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Abstract
L-asparaginase (ASP) is a key element in the treatment of paediatric acute lymphoblastic
leukaemia (ALL). However, hypersensitivity reactions (HSRs) to ASP are major challenges
in paediatric patients. Our aim was to investigate genetic variants that may influence the
risk to Escherichia coli-derived ASP hypersensitivity. Sample and clinical data collection
was carried out from 576 paediatric ALL patients who were treated according to protocols
from the Berlin—Frankfurt—Münster Study Group. A total of 20 single nucleotide polymor-
phisms (SNPs) inGRIA1 andGALNT10 genes were genotyped. Patients withGRIA1
rs4958351 AA/AG genotype showed significantly reduced risk to ASP hypersensitivity com-
pared to patients with GG genotype in the T-cell ALL subgroup (OR = 0.05 (0.01–0.26); p =
4.70E-04), while no such association was found in pre-B-cell ALL. In the medium risk group
two SNPs ofGRIA1 (rs2055083 and rs707176) were associated significantly with the occur-
rence of ASP hypersensitivity (OR = 0.21 (0.09–0.53); p = 8.48E-04 and OR = 3.02 (1.36–
6.73); p = 6.76E-03, respectively). Evaluating the genders separately, however, the associ-
ation of rs707176 with ASP HSRs was confined only to females. Our results suggest that
genetic variants ofGRIA1might influence the risk to ASP hypersensitivity, but subgroups of
patients can differ significantly in this respect.
Introduction
Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy, comprising
approximately 25–30% of the annually registered cases of cancer among children [1,2]. Survival
rates for paediatric and adolescent patients treated according to protocols by the Berlin—
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Frankfurt—Münster (BFM) Study Group have remarkably improved over the last decades with
higher than 80% of children are cured [1,3,4]. The extensive use of L-asparaginase (ASP),
which has been a crucial component of paediatric therapies since 1970s, contributes to this
achievement [5–9].
ASP enzymes mainly derived from bacteria among which three different preparations from
two bacteria are currently used: native and pegylated form of Escherichia coli ASP (E. coli-ASP
and PEG-ASP, respectively) and an Erwinia chrysanthemi-derived ASP (Erwinia-ASP) with
more or less different pharmacokinetic, pharmacodynamic and immunogenic properties [5].
Hypersensitivity reactions (HSRs) and silent inactivation via neutralizing antibody production
against the enzyme are major challenges in paediatric patients, because both can lead to subop-
timal treatment response. In addition, an anaphylactic reaction can be a potential threat to life
requiring urgent interventions [7].
In BFM protocols E. coli-ASP is considered as first-line treatment. Clinical HSRs occur in
up to 45% of paediatric ALL patients, which necessitate the discontinuation of E. coli-ASP
administration and subsequent switch to PEG-ASP or Erwinia-ASP [10–12]. The most com-
mon manifestation of HSRs is urticaria [13]. However, the signs and symptoms can range from
local reactions of erythema, swelling or pain at the injection site to severe symptoms, including
laryngeal edema, bronchospasm, hypotension and occasionally systemic anaphylaxis [14]. Sev-
eral risk factors of ASP hypersensitivity have been described including different preparations,
dosage, route of administration, readministration after a hiatus and concomitant chemother-
apy. However, this type of adverse reaction is unpredictable and exhibits large interindividual
differences [11].
Recently, a genome wide association study has been carried out in an ethnically diverse pop-
ulation to identify germline genetic variations contributing to the risk of ASP allergy in chil-
dren with ALL. In this study variants of the GRIA1 (Glutamate Receptor, Ionotropic, AMPA 1)
gene located at 5q33 have been found associated with ASP allergy [15]. This result has later
been replicated in a small Slovenian population [16].
In gene association studies, due to the high number of inconclusive results, it is generally
accepted that the role of a gene or a genetic variation can only be acknowledged, if it is con-
firmed by independent studies. In the present study our aim was to investigate the possible
roles of genetic variations in the GRIA1 gene in the susceptibility to E. coli-ASP hypersensitivity
in a large Hungarian paediatric ALL population. Additionally, we also involved SNPs in
GALNT10 (Polypeptide N-Acetylgalactosaminyltransferase 10) gene, located also at 5q33,
which in the original study were also found to be associated with ASP allergy in the discovery
cohort, but could not be confirmed in a relatively small validation cohort.
Patients and Methods
Study population
Samples and clinical data collection were carried out from 576 paediatric acute lymphoblastic
leukaemia (ALL) patients who were treated between 1990 and 2012 in 9 Hungarian paediatric
haematology centres according to four consecutive chemotherapy protocols from the Berlin—
Frankfurt—Münster Study Group (ALL-BFM 90, 95, ALL IC-BFM 2002 and 2009). These pro-
tocols in detail have been described elsewhere [3,4,17,18]. In this period of time two E. coli-
ASP, Kidrolase (Jazz Pharmaceuticals, Inc.) or Asparaginase medac (Kyowa-Hakko) were
available as first-line ASP preparations.
The treatment according to the different risk arms focusing on E. coli-ASP dosing schedules
with the number of patients included are shown in S1 Table. Comparison of the treatments on
different risk arms can also be found in S1 Text.
GRIA1 Polymorphisms and Asparaginase Hypersensitivity
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Data collection was carried out retrospectively from the files of the patients. We excluded 42
patients for the following reasons: lack of clinical information (n = 15), discontinuation of ASP
administration not due to hypersensitivity (n = 1), switch to a different type of ASP not due to
hypersensitivity (n = 1), genotyping call rate of the sample<50% (n = 28), significant deviation
from the protocol (n = 6) and use of other treatment protocols (10). The inclusion criterion for
controls was the completion of at least two blocks of E. coli-ASP containing treatment without
any HSR. Therefore, we excluded further ten patients. Finally, a total of 505 patients were
included in the analysis (Table 1).
The National Cancer Institute Common Toxicity Criteria (CTC) system v3.0 was used to
assess the grade of hypersensitivity. For analyses, we regarded a case as asparaginase hypersen-
sitivity when signs of allergic reactions or anaphylactic reactions CTC grade 1 and above were
noted which occurred during the infusion or within 4 hours, plus the clinical team decided to
discontinue, not readminister the given aparaginase preparation in the later treatments. The
descriptions of the HSRs were included in the medical records of the patients.
Written informed consent was obtained from the study participants or from the next of kin,
caretakers, or guardians on the behalf of the minors/children participants involved in the
study. All the associated documents have been stored. The study was conducted according to
the principles expressed in the Declaration of Helsinki and the whole study including the
informed consent procedure were approved by the Hungarian Scientific and Research Ethics
Committee of the Medical Research Council (ETT TUKEB; Case No.:8-374/2009-1018EKU
914/PI/08).
Genes and polymorphisms
SNPs of GRIA1 and GALNT10 genes were searched for in online databases. The criteria of the
SNP selection were the minor allele frequency10% in Caucasian population, their estimated
function based on dbSNP database of National Center of Biotechnology Information (NCBI;
www.ncbi.nlm.nih.gov) or any relevant results published previously [19,20]. In case of
GALNT10 the whole 3’-UTR region were covered (S2 Table).
Genotyping
In most cases, peripheral blood was obtained retrospectively from patients in remission phase.
In some cases, only diagnostic peripheral blood or bone marrow cell suspension samples were
Table 1. Patient characteristics.
Gender (%)
Male 280 (55.4)
Female 225 (44.6)
Years of age at diagnosis
Mean (± SD) 6.2 (±4.1)
Median (range) 4.9 (1–18)
Risk category (%)
Low Risk, LR 147 (29.1)
Medium Risk, MR 305 (60.4)
High Risk, HR 53 (10.5)
Immunophenotype (%)
pre-B ALL 402 (79.6)
T-ALL 69 (13.7)
doi:10.1371/journal.pone.0140136.t001
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available (n = 69). The genomic DNA was extracted by using the QIAamp DNA Blood Midi
Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. In case of low
amount or low concentration of DNA (a total of 87 samples) whole genome amplification was
performed by using the REPLI-g Mini Kit (Qiagen, Valencia, CA, USA) according to the man-
ufacturer’s instructions.
A total of 20 SNPs (10 in each gene) were genotyped by using KASPar-on-Demand prevali-
dated assays (LGC Genomics, Berlin, Germany) on 7900HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). The genotyping call rate for all SNPs was higher
than 80%.
Statistical analysis
Multi-adjusted logistic regression was performed by using IBM SPSS Statistic software, version
20.0 to test for associations. Gender, ALL immunophenotype, age at diagnosis, risk group, E.
coli-ASP dosage during induction phase, BFM protocol and the polymorphisms in additive (11
vs. 12 vs. 22), dominant (11 vs. 12/22) and recessive (11/12 vs. 22) models were included in the
analysis as categorical covariates (1, major allele; 2, minor allele). Odds ratios (ORs) and 95%
confidence intervals (CIs) were obtained to estimate risks for each SNP to E. coli-ASP hyper-
sensitivity. The analyses were performed not only for the overall ALL cohort, but also for sub-
groups created by gender, ALL immunophenotype (pre-B vs. T-ALL), age at diagnosis (10
years vs.<10 years) and risk category (standard vs. medium vs. high risk).
In order to deal with multiple comparisons the Benjamini-Hochberg false discovery rate
(FDR) method with type I error rate of 5% (p 6.76E-03) was applied as correction [21,22].
Power analysis was conducted by bootstrapping using R statistical software (R Foundation
for Statistical Computing, Vienna, Austria; version 3.0.3) in the following way. First, we simu-
lated 1 000 data replicates by sampling with replacement from the original dataset. Next, we
applied logistic regression to each generated data set, and estimated power as the percentage of
cases in which the null hypothesis was rejected.
Discrete-time survival analysis was used to assess the impact of SNPs on the minimum
number of doses at which E. coli-ASP hypersensitivity developed. The hazard rate of the i-th
patient was modeled by logistic regression:
logit hi ¼ aDi þ bXi
where D represents the minimum number of doses at which E. coli-ASP hypersensitivity devel-
oped by each study sample (more formally, for the i-th patient: Dij = 1, if the patient developed
allergy exactly at the j-th dose of ASP, and Dik = 0 for all dose counts k where k 6¼ j); Xi contains
the value of the covariate (SNP) that might predict hazard function differences, and α and β are
the appropriate regression coefﬁcients. Analyses were performed using R statistical software.
The deviation from Hardy-Weinberg Equilibrium (HWE) was analysed by χ2 goodness-of-
fit test using an online application (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
Results
We investigated the impact of GRIA1 and GALNT10 polymorphisms on the risk to E. coli-ASP
hypersensitivity in paediatric ALL patients.
Out of the 20 SNPs, 18 were statistically evaluated, since two of them did not meet the
requirements of HWE. The genotype and minor allele frequencies (MAF) with the results of
the HWE are shown in S2 Table.
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To examine the differences in genotype frequencies in patients with E. coli-ASP hypersensi-
tivity and patients without HSRs to E. coli-ASP, multi-adjusted logistic regression analyses
were applied on the overall cohort and on various subgroups.
Due to multiple testing, statistical corrections were applied. Applying FDR = 5% (p 6.76E-
03) significance threshold three SNPs in GRIA1 gene showed statistically significant associa-
tions on certain subgroups.
The association of rs4958351 with E. coli-ASP hypersensitivity was not replicated in our
total study cohort. The allele and genotype distributions for each SNP can be found in S3
Table. When we evaluated the associations between SNPs and E. coli-ASP hypersensitivity in
T-cell and pre-B-cell ALL separately, in case of rs4958351 a significant difference between the
subgroups was detected. In the dominant model patients with rs4958351 AA/AG genotype
showed significantly reduced risk to ASP hypersensitivity compared to patients with GG geno-
type in the T-ALL subgroup (OR = 0.05 (0.01–0.26); p = 4.70E-04; power = 0.78); Table 2). To
examine a more homogeneous group we also analysed T-ALL patients on MR arm. In this way,
the association still could be detected (N = 50; OR = 0.05 (0.01–0.29); p = 8.43E-04).
The overall rate of E. coli-ASP hypersensitivity was 37% (37%, 30% and 77% in standard
(SR), medium (MR) and high risk (HR) group, respectively). We found association between
two polymorphisms (rs2055083 and rs707176) and the occurrence of ASP hypersensitivity in
the MR group. On the one hand, in the dominant model, patients with rs2055083 AA/AG
genotype had significantly lower risk to develop ASP hypersensitivity compared to patients
with GG genotype (OR = 0.21 (0.09–0.53); p = 8.48E-04; power = 0.97; Table 3).
On the other hand, in recessive model, patients with CC genotype of rs707176 had signifi-
cantly higher risk to have ASP hypersensitivity until the end of the reinduction compared to
patients harbouring at least one T allele (OR = 3.02 (1.36–6.73); p = 6.76E-03; power = 0.73;
Table 4). The risk to E. coli-ASP hypersensitivity was approximately four times higher for
female patients with CC genotype compared to patients with at least one T allele (OR = 4.03
(1.48–10.94), p = 6.28E-03; power = 0.78), while no such association was found in male
patients.
When we evaluated the genders separately in each risk category, it turned out that in the
MR group the association of rs707176 with ASP HSR was confined only to females with a very
high OR (OR = 11.56 (2.56–52.27); p = 1.48E-03; Table 5).
The highest incidence of HSRs to E. coli-ASP in the MR group was observed during the first
dose of ASP in the reinduction (approximately 70% of the overall numbers of cases) after a
three-month-long break in ASP therapy. By the end of the E. coli-ASP treatment the cumula-
tive incidence of E. coli-ASP hypersensitivity was 34% (84 out of 244) and 11% (6 out of 55) for
patients with rs2055083 GG and AA/AG genotypes (p = 1.3E-3), respectively (Fig 1A). In case
of rs707176 this value was 48% (14 out of 29) and 27% (71 out of 264) for patients with CC and
CT/TT genotypes (p = 3.1E-2), respectively (Fig 1B). In order to be comparable we analysed
T-ALL subgroup restricted to MR patients: the cumulative incidence of E. coli-ASP hypersensi-
tivity was 60% (12 out of 20) and 10% (3 out of 30) for patients with GG and AA/AG genotypes
(p = 5.0E-4), respectively (Fig 1C). After completing the reinduction therapy on MR arm (a
total of 12 doses of E. coli-ASP) without any HSR to E. coli-ASP none of the patients developed
E. coli-ASP hypersensitivity in further blocks.
Furthermore, focusing on MR patients we used discrete-time survival analysis to assess the
effect of the SNPs on the minimum number of doses at which E. coli-ASP hypersensitivity
developed. A strong effect of rs2055083 could be detected on the minimum number of doses.
The hazard ratio of the minor A allele in dominant model was 0.25 (N = 299; 95% CI: (0.11–
0.60); p = 1.8E-03). This means that the hazard rate of patients who have at least one A allele is
approximately 75% less than that of the patients who are homozygous to the G allele. In
GRIA1 Polymorphisms and Asparaginase Hypersensitivity
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contrast, the minor C allele of rs707176 in recessive model was proved to be a strong risk factor
(N = 293; hazard ratio: 2.38; 95% CI: (1.23–4.62); p = 0.0105). We also found a strong effect of
rs4958351 on the minimum number of doses in the T-ALL subgroup on MR arm. The hazard
rate of patients harbouring at least one A allele was about 91% less than patients with GG geno-
type (N = 50; hazard ratio: 0.09; 95% CI: (0.02–0.36); p = 6.1E-04). Hence, the A allele of
rs4958351 appeared to be a preventive factor in T-cell ALL.
Univariate and multivariate logistic regression was applied to evaluate the differences in the
rate of E. coli-ASP hypersensitivity in various subgroups. Patients on HR treatment arm had
significantly increased odds of developing E. coli-ASP hypersensitivity compared to those on
SR and MR arm (OR = 5.88 (2.85–12.15); p = 2.00E-06 and OR = 10.50 (2.82–39.02);
p = 4.49E-04, respectively). We found no differences in E. coli-ASP hypersensitivity rate
between further subgroups (Table 6).
Discussion
The aim of our study was to investigate the impact of genetic variants of GRIA1 and GALNT10
genes on ASP allergy in a large Hungarian population of 576 ALL patients. We identified one
synonymous and two intronic GRIA1 SNPs associated with E. coli-ASP hypersensitivity on cer-
tain ALL subgroups. We could find no association regarding the GALNT10 polymorphisms.
Previously, Chen et al. analysed more than 500,000 SNPs in a genome-wide association
study of 485 children with ALL. They found that the rs4958351 and four additional intronic
SNPs of the GRIA1 gene on chromosome 5q33 region were associated with ASP
Table 2. Associations of rs4958351 with the occurrence of E. coli-ASP hypersensitivity in the total cohort and in the immunophenotypic
subgroups.
rs4958351
GG vs. AG/AA
Subgroup N p value OR (95% CI)
Total 464 0.500 0.87 (0.58–1.31)
Immunophenotype pre-B ALL 364 0.522 1.16 (0.73–1.85)
T-ALL 66 4.70E-04 0.05 (0.01–0.26)
Results that reached the signiﬁcance threshold (FDR(α) = 5%; p 6.76E-03) are in bold.
doi:10.1371/journal.pone.0140136.t002
Table 3. Associations of rs2055083 with the occurrence of E. coli-ASP hypersensitivity in the total
cohort and in different risk groups.
rs2055083
GG vs. AG/AA
Subgroup N p value OR (95% CI)
Total 490 0.104 0.66 (0.39–1.09)
Risk category SR 141 0.090 2.08 (0.89–4.84)
MR 298 8.48E-04 0.21 (0.09–0.53)
HR 51 0.245 4.73 (0.34–64.90)
Results that reached the signiﬁcance threshold (FDR(α) = 5%; p 6.76E-03) are in bold.
doi:10.1371/journal.pone.0140136.t003
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PLOS ONE | DOI:10.1371/journal.pone.0140136 October 12, 2015 6 / 12
hypersensitivity [15]. Recently, these results were replicated in an independent, relatively small
Slovenian population of 146 paediatric ALL patients [16]. Chen et al. also identified genetic
variants of GALNT10 (located in the same region) in the initial cohort of 322 paediatric
patients, but these associations could not be detected in the smaller validation cohort of 163
children [15].
GRIA1 encodes a subunit (GluR1) of the ionotropic alpha-amino-3-hydroxy-5-methyl-
4-isoxazole propionate (AMPA) receptor. These receptors are homomeric or heteromeric pro-
tein complexes consisting of GluR1-4 subunits, which are arranged to form a ligand-gated ion
channel transmitting glutamatergic signals in the central nervous system (http://www.
genecards.org/cgi-bin/carddisp.pl?gene=GRIA1).
Recent studies have shown that glutamate acts also as an immunomodulator in addition to
being a neurotransmitter [15,16,23]. For the first time, in 2001 Lombardi et al. described the
presence of ionotropic glutamate receptors (iGluRs) on the surface of human T-lymphocytes.
The same study has revealed the functionality of AMPA receptors by potentiation of Ca2+
influx upon T-cell activation [24]. Later, other studies have demonstrated that glutamate
induced both a pro-adhesive and a pro-migratory effect on naïve/resting T-cells by acting via
its AMPA receptors [25–27]. Moreover, the expression of several glutamate receptors and
transporters has been described in various types of immune cells including dendritic cells
(DCs). DCs release glutamate upon interacting with T-lymphocytes in lymph nodes. Pacheco
et al. demonstrated that during this interaction glutamate acts as a highly effective regulator in
the initiation of T-cell mediated immune responses [27]. Besides, in addition to the ab ovo ele-
vated level of plasma glutamate due to malignancy, the glutaminase activity of E. coli-ASP
results in a significant rise of the cleavage product glutamate during treatment with a high
interindividual variability [28]. Taken together, these data suggest that genetic polymorphisms
of glutamate signalling pathways in immune system may influence the risk of developing ASP
hypersensitivity.
The rs4958351 SNP showed no association with E. coli-ASP hypersensitivity in our total
study cohort. However, we found that the effect of the A allele drastically differs on the suscep-
tibility to ASP hypersensitivity in the different subtypes of ALL. While it is associated with sig-
nificantly reduced risk to HSR in T-cell ALL (OR = 0.05), it is associated with a slightly
although not significantly increased risk to HSR in pre-B-cell ALL. In contrast, Chen et al. and
Table 4. Associations of rs707176 with the occurrence of E. coli-ASP hypersensitivity in the total
cohort and in different subgroups.
rs707176a
CT/TT vs. CC
Subgroup N p value OR (95% CI)
Total 477 0.041 1.90 (1.02–3.48)
Risk category SR 136 0.689 1.25 (0.42–3.68)
MR 292 6.76E-03 3.02 (1.36–6.73)
HR 49 0.385 0.36 (0.03–3.66)
Gender Male 263 0.770 1.14 (0.48–2.66)
Female 214 6.28E-03 4.03 (1.48–10.94)
Results that reached the signiﬁcance threshold (FDR(α) = 5%; p 6.76E-03) are in bold.
a the cofactor of ASP dosage during induction was not included in the analysis due to numerical problems
of the logistic regression model created by the presence of cell values equal to zero.
doi:10.1371/journal.pone.0140136.t004
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Rajić et al. have identified the A allele as a risk allele in the whole ALL cohort. However, per-
haps because of the low number of T-ALL patients in their study cohorts, the different immu-
nophenotypic subgroups have not been evaluated separately. To our knowledge, ours is the
first study on the relation of rs4958351 to the risk of E. coli-ASP hypersensitivity in T-ALL as a
separate subgroup; hence this opposite association in this subgroup of ALL patients could have
been hidden up to this point.
In our study the intronic rs2055083 polymorphism in the GRIA1 gene appeared to be a
strong preventive factor of E. coli-ASP hypersensitivity in a homogeneous cohort of MR ALL
patients. No result has been published so far related to rs2055083. According to the results of
the 1000 Genomes Project the rs2055083 is in linkage disequilibrium (LD) with another intro-
nic SNP rs10515693 (http://www.ensembl.org/Homo_sapiens/Variation/HighLD?db = core;r=
5:153487464-153667465;v = rs2055083;vdb = variation;vf=1720088#13083_tablePanel; r2 =
0.953; D’ = 1.000; Ensembl release 81—July 2015) in the CEPH population. However, in the
European (EUR) super population the regarding values were lower (r2 = 0.7; D’ = 0.85). Using
Table 5. Associations of rs707176 with the occurrence of E. coli-ASP hypersensitivity in subgroups created by risk category and gender.
rs707176a
CT/TT vs. CC
Subgroup N p value OR (95% CI)
Risk category SR Male 65 0.806 1.24 (0.23–6.77)
Female 71 0.726 1.30 (0.30–5.74)
MR Male 165 0.767 1.19 (0.38–3.77)
Female 127 1.48E-03 11.56 (2.56–52.27)
HR Male n.a.b n.a.b n.a.b
Female n.a.b n.a.b n.a.b
Results that reached the signiﬁcance threshold (FDR(α) = 5%; p 6.76E-03) are in bold.
a the cofactor of ASP dosage during induction was not included in the analysis due to numerical problems of the logistic regression model created by the
presence of cell values equal to zero.
b not analysed due to the presence of cell values equal to zero.
doi:10.1371/journal.pone.0140136.t005
Fig 1. The cumulative incidence of E. coli-ASP hypersensitivity with the number of ASP doses. (A) In case of rs2055083 the cumulative incidence of E.
coli-ASP by the end of the of the second block on MR arm was 34% (84 out of 244) and 11% (6 out of 55) for patients with GG and AA/AG genotypes,
respectively. (B) In case of rs707176 the same value was 48% (14 out of 29) and 27% (71 out of 264) for patients with CC and CT/TT genotypes,
respectively. (C) Analysing T-ALL patients on MR arm the cumulative incidence of E. coli-ASP hypersensitivity by the end of the of the second block was 60%
(12 out of 20) and 10% (3 out of 30) for patients with GG and AA/AG genotypes, respectively.
doi:10.1371/journal.pone.0140136.g001
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the online Variant Effect Predictor (VEP) tool of Ensembl it has been revealed that the latter
polymorphism is located in a regulatory region (ENSR00001294367), which is active in a
human B-lymphocyte cell line GM12878 and acts as an enhancer (http://www.ensembl.org/
Homo_sapiens/Regulation/Summary?db = core;fdb = funcgen;r=5:153554305-153557304;rf=
ENSR00001294367;tl = gEE3ksgDRibSzsCu-737322). Based on this, one possible reason of
association between rs2055083 and ASP allergy that rs2055083 is in LD with a regulatory vari-
ant in B-lymphocytes.
It has been shown in an Italian case-control association study that the allele distributions of
rs707176 were different in DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition, Text Revision) schizophrenia controls and in cases [20]. In our study
population this SNP, which is a synonymous C/T transition in exon 3 of the GRIA1 gene, was
associated with E. coli-ASP hypersensitivity in MR subgroup (p = 6.76E-03). The risk of CC
homozygotes to HSR was very high in females (OR = 4.03 (1.48–10.94)), while no such effect
could be observed in males which suggests a sex difference in the genetic background of ASP
hypersensitivity.
All the genetic variations we genotyped inGRIA1 gene were intronic or synonymous variants.
The functionality of these so-called silent polymorphisms is not yet clear. Intronic polymor-
phisms in the glutamate receptor subunit GluR2 have roles in directing RNA editing of the
GluR2 coding sequence [15,16,29]. Furthermore, it is known thatGRIA1 has alternatively spliced
transcript variants encoding different isoforms (http://www.genecards.org/cgi-bin/carddisp.pl?
gene=GRIA1). Emerging data show that the fine balance of alternative splicing isoforms may
also be altered by variants of exonic or intronic splicing regulatory elements [30]. These findings
suggest mechanisms by which these silent polymorphisms could influence gene function.
Table 6. Differences between subgroups in E. coli-ASP hypersensitivity.
Subgroup N cases / N total
(%)
Univariate p
value
OR (95% CI) Multivariate p
value
OR (95% CI)
Gender Male 99/280 (35.4) ref.* ref.*
Female 87/225 (38.7) 0.444 1.15 (0.80–
1.66)
0.225 1.27 (0.86–
1.87)
Immunophenotype pre-B ALL 152/402 (37.8) ref.* ref.*
T-ALL 26/69 (37.7) 0.984 0.99 (0.59–
1.68)
0.854 0.99 (0.47–
1.56)
Age at diagnosis <10 years 151/413 (36.6) ref.* ref.*
10 years 35/92 (38.0) 0.790 1.07 (0.67–
1.70)
0.921 1.03 (0.60–
1.75)
Risk Category Standard
Risk
54/147 (36.7) ref.* ref.*
Medium Risk 91/305 (29.8) 0.142 0.73 (0.48–
1.11)
0.512 0.86 (0.54–
1.37)
High Risk 41/53 (77.4) 2.00E-06 5.88 (2.85–
12.15)
4.49E-04 10.50 (2.82–
39.02)
Dosage of E. coli-ASP during
induction**
5000 IU/m2/d 53/138 (38.4) ref.* ref.*
10000 IU/m2/
d
91/310 (29.4) 0.059 0.67 (0.44–
1.02)
0.398 1.93 (0.42–
8.78)
Results that reached the signiﬁcance threshold (p 0.05 in univariate and FDR(α) = 5%; p 6.76E-03 in multivariate analysis) are in bold.
* ref. refers to the reference group to which the others groups are to be compared
** on standard and medium risk arm
doi:10.1371/journal.pone.0140136.t006
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We tested the differences in the occurrence of E. coli-ASP hypersensitivity by logistic regres-
sion between subgroups created by gender, age at diagnosis, risk category, immunophenotype
of leukaemia and the dose of E. coli-ASP during induction on SR and MR arms. HR patients
were at approximately six times higher odds of developing E. coli-ASP hypersensitivity com-
pared to SR patients (p = 2.00E-06). The occurrence of E. coli-ASP hypersensitivity did not dif-
fer significantly between the SR and the MR groups. These findings can be explained by the
considerably different treatment with more and greater doses of ASP as well as with many
breaks in ASP therapy on HR arm compared to SR and MR arms.
The highest occurrence of E. coli-ASP hypersensitivity reactions was after a three-month-
long break (consolidation phase) in ASP treatment during the first dose of reinduction on MR
arm. It is in accordance with previously observed phenomena that reexposure of ASP after a
hiatus increases the risk to HSRs [10,11]. The proliferation and antibody production of compe-
tent B-cells during consolidation can be one of the possible explanations [16,31].
This study has several strengths and limitations. First, although the rate of relapsed patients
of our cohort is similar to the relapse rate of the whole ALL population, the rate of died
patients, however, is lower in our study population. Patients who died during the chemother-
apy due to therapy resistant progressive disease or due to infections or toxicities of therapy are
underrepresented in our ALL cohort. Furthermore, HSR data to E.coli-ASP was collected retro-
spectively from the files of the patients. This manner does not allow meticulous documentation
and fine grading of hypersensitivity reactions.
Our findings pertain to reactions to E. coli-ASP. Fernandez et al. recently reported that the
association between the rs4958351 variant and hypersensitivity was strongest among patients
receiving native E. coli asparaginase compared to PEG-asparaginase [32].
A small proportion of our DNA samples had been originated from the diagnostic clone of
lymphoblasts. We hypothesized that the probability of the genetic alteration of the investigated
polymorphisms was extremely low during leukaemogenesis. To verify this, we also performed
the analysis excluding these samples and calculated the allele frequencies for the remission and
for the diagnostic samples. Even in this way, the results remained statistically significant and
we could not find substantial differences in the allele frequencies either (data not shown).
In conclusion, in our relatively large population we confirmed that genetic variations in the
GRIA1 gene could significantly influence the risk of ASP hypersensitivity. Furthermore, we
found that the direction of the effect could be significantly different in the different subgroups
of patients. In addition to previously published associations, we identified novel polymor-
phisms, which may serve to enlighten new details in the genetic background of E. coli-ASP
hypersensitivity reactions. Replication in other cohorts is warranted to confirm our findings.
Functional analysis of variants is needed, especially in case of the rs4958351 in T-ALL to eluci-
date its role in ASP allergy development.
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